

## Clinical Benefit and Other Indications for Biologics

| Biologic                    | Omalizumab (Anti-IgE)                       | Mepolizumab (Anti-IL5)      | Benralizumab (Anti-IL5R)                 | Dupilumab (Anti-IL4R)  | Tezepelumab (Anti-TSLP) | Remarks   |
|-----------------------------|---|-----------------------------|--|--|-------------------------|---|
| <b>Dosing</b>               | 2-weekly or 4-weekly                        | 4-weekly                    | 4-weekly for 3 doses then 8-weekly after | 2-weekly   | 4-weekly                |   |
| <b>Clinical Benefits</b>    |   |                             |  |  |                         |   |
| <b>Symptom Control</b>      | Improve*                                    | Improve*                    | Improve*                                 | Improve*   | Improve*                |   |
| <b>Exacerbations</b>        | Reduce                                      | Reduce                      | Reduce                                   | Reduce   | Reduce                  | Greater reduction in Anti-IL4R and Anti-TSLP                          |
| <b>Lung function</b>        | Improve*                                    | Improve*                    | Improve*                                 | Improve*   | Improve*                | Greatest improvement in Anti-IL4R and Anti-TSLP                       |
| <b>Oral corticosteroids</b> | Reduce                                      | Reduce                      | Reduce                                   | Reduce   | Nil                     | Anti-IL5/5R most effective in reducing and discontinuation of OCS use |
| <b>Other indications</b>    | - Chronic spontaneous urticaria<br>- CRSwNP | - CRSwNP<br>- EGPA<br>- HES | - EGPA (pending FDA)                     | - CRSwNP<br>- Atopic Dermatitis<br>- Eosinophilic Oesophagitis<br>- Prurigo nodularis<br>- Eosinophilic COPD (pending FDA) |                         |   |

\*Did not meet minimal clinically important difference (MCID)

### Abbreviations:

CRSwNP: Chronic Rhinosinusitis with Nasal Polyps

EGPA: Eosinophilic granulomatosis with polyangiitis

HES: Hypereosinophilic Syndrome

COPD: Chronic Obstructive Pulmonary Disease